Business Context and Reporting Period
This Form 8-K was filed by Trovagene, Inc. (not Cardiff Oncology, Inc.) on July 10, 2018, reporting events occurring on July 9, 2018. The filing serves as a current report to update stakeholders on key value-creating milestones for the second half of 2018 and to review year-to-date achievements.
Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notification of a press release rather than a financial statement.
Material Changes
No material financial changes or comparative period data are disclosed in this filing. The primary event is the issuance of a press release regarding operational milestones.
Guidance, Outlook, and Risks
Management provided an update on key value-creating milestones for the second half of 2018 and a review of year-to-date achievements. The full details of this outlook and any associated risks are contained in the press release furnished as Exhibit 99.1, which is not included in the provided text. No specific guidance numbers or unusual items are detailed in the filing body.
Key Facts for Investor Verification
- Verify the company name: The filing is for Trovagene, Inc., not Cardiff Oncology, Inc.
- Review Exhibit 99.1 (Press Release dated July 9, 2018) for specific details on milestones and achievements.
- Note that no financial data is contained within this specific 8-K filing.
- Confirm the leadership status: Thomas Adams is listed as Interim Chief Executive Officer.